Metabolic Longevity · 20mg × 10 vials
In plain terms: Cardiogen is a research compound — oral, fast-acting and well studied.
Cardiogen is the Khavinson cardiac bioregulator: a short synthetic peptide, the tetrapeptide Ala-Glu-Asp-Arg (AEDR), modeled on the active fraction of the polypeptide complex originally extracted from bovine cardiac tissue (the parent extract is Chelohart, the Cytomax-line cardiac polypeptide complex) at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson in the 1990s-2000s. It sits in the Khavinson short-peptide series alongside Epithalon (AEDG tetrapeptide, pineal), Vilon (KE dipeptide, immune), Thymogen (EW dipeptide, immune T-helper axis), Cartalax (AED tripeptide, cartilage), Livagen (KEDA tetrapeptide, liver), Bronchogen (AEDL tetrapeptide, bronchopulmonary), Prostamax (AEDG variant, prostate), and Testagen (KEDG, testes). Mechanism is the Khavinson bioregulator paradigm: tissue-targeted short peptides that bind regulatory regions of DNA in their target cell population (the Khavinson group's molecular work describes direct interaction of these short peptides with histone-bound chromatin and promoter sequences in tissue-specific genes), shift gene expression in cardiomyocytes and surrounding cardiac tissue back toward a younger pattern, and rebalance the cellular populations that drive cardiac function. Published Khavinson-group work in aged-rat cardiac tissue and isolated cardiomyocyte models reports restored expression of contractile-protein genes (myosin heavy chain isoform shift back toward alpha-MHC from the senescent beta-MHC pattern), normalized calcium-handling protein expression (SERCA2a, phospholamban), reduced markers of cardiomyocyte apoptosis after ischemic stress, improved ejection-fraction-equivalent contractile metrics in animal models, and a normalization of the cardiac antioxidant defense (SOD, catalase, glutathione peroxidase activity restored toward younger-animal baselines). There is also a vascular component documented in some Russian-language work: improved endothelial nitric-oxide signaling and reduced markers of arterial wall senescence with chronic biannual pulsing. In plain customer language: Cardiogen is the cardiac-targeted bioregulator in the Khavinson short-peptide series, it pulses cardiomyocytes and the surrounding vascular tissue back toward a younger gene-expression pattern, and the effects persist between pulses because the change is at the cellular-population and gene-expression lev
Typical dose ranges by experience level — educational reference. Message us and we tailor it to you.
Conservative entry for cardiovascular-curious customers and post-MI recovery contexts where a gentler signal is appropriate for the first pulse. One CARDI20MG vial covers roughly 7-10 days at 2-3 mg, so a single vial covers most of a beginner pulse. Subjective signal during the pulse is mild; healthy users typically report nothing during the 10 days. Symptomatic users (post-MI fatigue, exertional dyspnea, age-related chest tightness) occasionally report a felt easing in the 2-6 weeks after the pulse, which the Khavinson framing attributes to restored cardiomyocyte gene expression rather than acute action.
5 mg/day for 10 days is the dose most community Khavinson-protocol users land on for Cardiogen, mirroring the dose range used in the Russian cardiology cohort reports. One 20 mg vial covers four 5 mg doses, so a full 10-day intermediate pulse needs 2.5 vials (3 vials in practice, with leftover for a top-up the next pulse). Customers running biannual intermediate pulses go through 5-6 vials per year, roughly $225-$270 per year at members-tier pricing. This is the dose most cardiovascular-longevity customers settle at after their first beginner pulse confirms tolerance.
10 mg/day matches the dose the Khavinson group used in the cardiology elderly cohorts for symptomatic post-MI and ischemic-heart-disease patients, often run as a 20-day extended course in the original Russian protocol rather than the 10-day pulse used for the more general longevity cadence. One 20 mg vial covers two days at 10 mg, so a 10-day advanced pulse burns 5 vials and a 20-day extended pulse burns 10 vials (one full kit-equivalent). Advanced users running Cardiogen for a documented cardiac context almost always pair it with SS-31 (the mitochondrial-cardiolipin layer) and often with MOTS-c (mitochondrial biogenesis) in the same window. The 5 mg BID compression protocol is community-driven rather than from Khavinson originals and is used by customers who want to spread the daily exposure across the day.
Straight talk — what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines — tap any to read the source.
foundational text on the Khavinson tissue-specific short-peptide bioregulator paradigm including the cardiac peptide family
Read study ↗PubMedKhavinson VK — Peptides and Ageing, Neuro Endocrinol Lett 2002 vol 23 suppl 3foundational review of the Khavinson short-peptide longevity program including Cardiogen
Read study ↗PubMedKhavinson VK, Lin'kova NS, Tarnovskaya SI — Short peptides regulate gene expression, Bull Exp Biol Med 2016Khavinson short peptides including the cardiac tetrapeptide regulate target gene expression in tissue-specific cell populations
Read study ↗PubMedKhavinson VK, Kuznik BI, Tarnovskaya SI, Lin'kova NS — Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data, Adv Gerontol 2014Khavinson cardiac and other tissue-specific short peptides in aging biomarker context
Read study ↗PubMedAnisimov VN, Khavinson VK — Peptide bioregulation of aging: results and prospects, Biogerontology 2010comprehensive review of the Khavinson peptide bioregulator program including cardiac peptide cohort outcomes
Read study ↗PubMedKhavinson VK, Morozov VG — Peptides of pineal gland and thymus prolong human life, Neuro Endocrinol Lett 200312-year follow-up Khavinson elderly cohort, 1.6-1.8x mortality reduction with biannual bioregulator pulses, includes cardiac context
Read study ↗Aggregated sentiment from public forums & socials — real-world reports, not individual endorsements.
Subtle to no perceptible signal during the 10-day pulse in healthy longevity users: the most consistent community theme across all Khavinson short peptides, Cardiogen included. The benefit is framed as cumulative across multi-year biannual pulsing rather than acute felt response.
Felt easing in symptomatic users: post-MI customers, customers with exertional dyspnea, customers with age-related chest tightness or diastolic dysfunction occasionally report a felt improvement 2-6 weeks after the pulse window. Community reports describe it as "things feel easier" rather than as a specific change in any single metric. Selection bias here:…
Mild fatigue or "off" feeling in first 1-2 days of pulse: occasional, less common than with the immune dipeptides, self-resolving.
Injection site stinging: occasional, generally mild.
Skepticism in the small Western community: same pattern as with Vilon, Thymogen, and Cartalax. The signal is subtle, the evidence base is mostly Russian-language, and the cultural expectation has been shaped by acute-effect compounds. Customers running Cardiogen alongside SS-31 often attribute the felt cardiac signal to SS-31 (which has a much clearer…
- Divergence: Russian literature emphasizes echocardiographic, ECG, and gene-expression endpoints (ejection fraction shifts, contractile-protein expression, cardiomyocyte apoptosis markers, calcium-handling protein restoration), and the elderly cardiology cohort reports describe symptomatic improvement in angina frequency and exertional capacity.…
Route: SubQ injection is the PP default and the community-standard outpatient route. The Khavinson Russian literature documents both injection and oral capsule formats for the tetrapeptide bioregulators (NANOPEP / Peptide-Products sells Cardiogen capsules used 1/day for the same 10-day pulse cadence, and the original Russian elderly cardiology cohorts used oral courses extensively). PP ships injectable lyophilized 20 mg vials, so SubQ is the route to brief customers on. Sublingual administration of the reconstituted solution is a workable alternative that some users default to.
Injection site: abdomen, outer thigh, or upper outer arm; rotate sites across the 10-day pulse. No need to inject anywhere near the heart; this is a systemic SubQ peptide.
Storage: refrigerated, ~28 days after reconstitution. Lyophilized vials store at room temp short-term, refrigerate or freeze for longer hold. The AEDR tetrapeptide is reasonably stable as a defined small synthetic; the 10-day pulse falls well inside the 28-day reconstituted window.
Notes: No strict timing window. Evening dosing pairs cleanly with concurrent Epithalon (also evening) when running a biannual Khavinson combo. Don't shake the vial; swirl gently. As a defined synthetic tetrapeptide, Cardiogen does not have the batch-to-batch potency variability concern of biological extracts. Customers running SS-31 or MOTS-c in the same window can dose Cardiogen at the same time or shift to morning; no clinically meaningful timing conflict.